Results 221 to 230 of about 35,603 (297)

Community pharmacists' practices and perspectives on deprescribing high‐risk psychotropic medicines: National survey findings

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To explore the practices, confidence and perspectives of community pharmacists in deprescribing high‐risk psychotropic medicines, including opioid analgesics, benzodiazepine, gabapentinoids and medicinal cannabis. Methods An anonymous, cross‐sectional national online survey was conducted between January and April 2025 among Australian community ...
Monica Jung   +5 more
wiley   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove   +4 more
wiley   +1 more source

Career commitment and sense of calling in nursing students: a longitudinal study. [PDF]

open access: yesFront Med (Lausanne)
Ding T   +7 more
europepmc   +1 more source

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aim To evaluate the effects of carbamazepine, a strong cytochrome P450 (CYP)3A4 inducer, on the pharmacokinetics and safety of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader. Methods This was a phase 1, open‐label, fixed‐sequence, two‐period study in healthy adult participants.
Hechuan Wang   +7 more
wiley   +1 more source

Do drugs approved via expedited approval pathways have therapeutic advantages? A systematic review and meta‐analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Regulators use expedited approval pathways to speed market approval and patient access to promising new drugs. However, there is uncertainty about whether these pathways are successful in approving drugs with significant therapeutic advantages. This systematic review aims to examine the safety, effectiveness and cost‐effectiveness of drugs approved via
Ashleigh Hooimeyer   +4 more
wiley   +1 more source

Completion vs. early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Chemotherapy is given for early‐stage breast cancer; however, some patients discontinue before completing all planned cycles. This study investigated the impact of early chemotherapy discontinuation on treatment outcomes. Methods This retrospective cohort study used a target trial emulation framework to conduct a causal analysis of the all‐
Luke Steventon   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy